ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mibavademab

Also written as “Mibavademab”, “REGN4461” and “Low-Dose REGN4461”.

Its studies are mostly in Obesity, Morbid · Lipodystrophy, Familial Partial · Amenorrhea · Obesity, led by 2 companies.

Drug pageMibavademab: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 7, 20248 company-led studies, 3 open or runningNext primary completion: Jun 18, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals73 open or runningphase 3since Aug 7, 2024May 7, 2018Jun 18, 2027phase 3 · NCT07220772
Eli Lillyits history only10 open or runningphase 2since Apr 16, 2024Apr 16, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Regeneron Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 7, 2018First study: phase 1 study in Healthy VolunteersFirst studyNCT03530514 · 113 enrolled · Belgium
  2. Nov 7, 2019Phase 2 study in Lipodystrophy, Congenital GeneralizedNCT04159415 · 16 enrolled · United States, Peru, Russia and more
  3. Dec 19, 2020Named mibavademabINNProposed as its International Nonproprietary Name in WHO's List 124 · before, REGN4461
  4. Oct 12, 2021Phase 2 study in Lipodystrophy, Familial PartialNCT05088460 · 20 enrolled · United States, France, Spain and more
  5. Aug 7, 2024Phase 3 study in Lipodystrophy, Congenital GeneralizedNCT06548100 · 9 enrolled · United States
  6. Oct 22, 20252 phase 3 studiesNCT07220785, NCT07220772
  7. Nov 14, 2025Phase 2 study in AmenorrheaNCT07235917 · 34 planned · United States
  8. Oct 1, 2026Primary completion moved from 2027-08-20 to 2028-01-28Date moved laterphase 2 · +5 months · NCT07235917

Ahead

  1. Jun 18, 2027Primary completion: phase 3 study in Obesity, MorbidNCT07220772
  2. Jan 28, 2028Primary completion: phase 2 study in AmenorrheaNCT07235917
  3. May 19, 2028Primary completion: phase 3 study in Lipodystrophy, Congenital GeneralizedNCT07220785

TargetBeta

LEPR →read by rule
“Leptin receptor agonist”ChEMBL 37, by rule

Studies

All 7 Regeneron Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07235917Amenorrhea · United States2RecruitingJan 28, 202834
NCT07220785Lipodystrophy, Congenital Generalized · United States, Brazil, France3RecruitingMay 19, 202828
NCT07220772Obesity, Morbid · Germany, Spain, Turkey (Türkiye)3RecruitingJun 18, 20274
NCT06548100Lipodystrophy, Congenital Generalized · United States3CompletedJul 9, 20269
NCT05088460Lipodystrophy, Familial Partial · United States, France, Spain and more2TerminatedDec 13, 202320
NCT04159415Lipodystrophy, Congenital Generalized · United States, Peru, Russia and more2CompletedJan 5, 202216
NCT03530514Healthy Volunteers · Belgium1CompletedJan 27, 2020113

How it is read

Names in the registry

  • “Mibavademab”, 4 entries
  • “REGN4461”, 2 entries
  • “mibavademab”, 1 entry
  • “Low-Dose REGN4461”, 1 entry
  • “High-dose REGN4461”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.